Neurology

Eisai will present four-year safety and efficacy data, real-world use patterns, and findings on a new subcutaneous formulation for maintenance treatment in early Alzheimer disease.

In recognition of World Brain Day, Anna Chodos, MD, discusses why early detection of cognitive decline must become standard practice—and how PCPs can take simple, effective steps to make that happen.

Libon, a professor at the New Jersey Institute for Successful Aging at Rowan University, says the refined approach to cognitive assessment is widely available.

World Brain Day is celebrated on July 22 every year. In recognition Patient Care has summarized 9 notable studies of key interest to primary care for quick review.

Digital latency measures enhance early detection of cognitive decline, revealing neurodegenerative changes before traditional tests indicate impairment.

For the often treatment-resistant pain of neuropathic conditions, the meta-analysis includes updated evidence for both pharmacologic and neuromodulatory interventions.

The adjusted dosing for donanemab in early AD reduced ARIA-E risk by 41% compared to the original dosing, without compromising efficacy.

The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.

The StateViewer clinical decision support system could help expand access to specialist-level insights in clinics that lack neurology expertise, according to researchers.

The adjuvanted RSV vaccine, in particular, was associated with a 29% reduction in the risk of dementia in the subsequent 18 months, a University of Oxford study found.

Suboptimal adherence with antidementia drugs is associated with poorer clinical outcomes including accelerated disease progression and symptomatology.

Primary care clinicians are generally the first clinical contact for older adults with early signs of dementia. Our survey uncovered 5 primary challenges to being in that role.

The FDA cleared Happy Ring, a wearable device for at-home diagnosis of sleep disorders, enhancing access to vital sleep health solutions.

The superior tolerability and efficacy of the CGRP-targeting atogepant supports recent calls from the AHS to consider the class as first-line preventive therapy for migraine.

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.

New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

AUD affects 15 million Americans, with men nearly 2 times more vulnerable to the disease vs women. Are you tracking signs and symptoms in your patients?

Solriamfetol's significant cognitive benefits may be the result of mechanisms operating independently of its wake-promoting effects, study authors suggest.

Authors say their findings support the accumulating evidence that late-life mood disorders may be a prodromal manifestation of dementia vs a risk factor alone.

Cycling and mixed cycling were associated with a reduced risk of all-cause dementia, including of young onset, as well as increased hippocampal volume.

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.

Senate hearing reveals tensions between scientific consensus and HHS Secretary Kennedy's claims on Alzheimer research funding and priorities.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Adults with early AD who were treated with lecanemab in a specialty memory clinic experienced adverse events comparable to those seen in clinical trials.

The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.